Companies Damora Therapeutics, Inc.
Damora Therapeutics (DMRA): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Email me Damora Therapeutics, Inc.’s executive pay brief as a PDF
It arrives in about 2 minutes, with every figure cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $965,115FY2023
- $1,429,550FY2024
- $1,299,792FY2025
CEO total pay was $1,299,792 in fiscal 2025, down from $1,429,550 in fiscal 2024.
FY2025: salary $547,521 · bonus $678,594 · stock awards $0 · option awards $73,677
Order DMRA
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.
Executives and directors
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Hans Schambye | $547,521 | $678,594 | $0 | $73,677 | $0 | $0 | $0 | $1,299,792 |
| Former President and Chief Executive Officer | ||||||||
| Garrett Winslow | 400,400 | 400,400 | 0 | 26,955 | 0 | 0 | 27,000 | 854,755 |
| General Counsel | ||||||||
| Lori Firmani | 311,249 | 202,500 | 0 | 22,463 | 0 | 0 | 27,000 | 563,211 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Hans Schambye | $1,299,792 | $1,429,550 | $965,115 | ↓ −129,758 |
| Garrett Winslow | 854,755 | 897,368 | 554,388 | ↓ −42,613 |
| Lori Firmani | 563,211 | 561,892 | — | ↑ +1,319 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The company's compensation program is designed to reward named executive officers for meeting objective or subjective performance goals for a fiscal year. The Board of Directors or Compensation Committee approves annual bonuses based on individual performance, company performance, or as otherwise determined appropriate.
| CEO STI target (% of salary) | NaN% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | The insider trading policy prohibits directors, executive officers, and employees from engaging in hedging transactions with respect to the Company's securities unless approved by the Audit Committee. |
| Anti-pledging | The insider trading policy prohibits directors, executive officers, and employees from pledging the Company's stock as collateral for a loan unless approved by the Audit Committee. |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Hans Schambye | Option | 239 | 81 | — |
| Lori Firmani | Option | 305 | 81 | — |
| Garrett Winslow | Option | 375 | 140.25 | — |
| Garrett Winslow | Option | 609 | 81 | — |
| Lori Firmani | Option | 703 | 30.25 | — |
| Lori Firmani | RSU | 1,100 | — | 25,311 |
| Garrett Winslow | Option | 1,250 | 30.25 | — |
| Garrett Winslow | RSU | 2,000 | — | 46,020 |
| Hans Schambye | Option | 3,250 | 30.25 | — |
| Hans Schambye | RSU | 4,000 | — | 92,040 |
| Lori Firmani | Option | 5,000 | 5.7 | — |
| Garrett Winslow | Option | 6,000 | 5.7 | — |
| Lori Firmani | Option | 9,208 | 7.49 | — |
| Garrett Winslow | Option | 11,050 | 7.49 | — |
| Hans Schambye | Option | 16,400 | 5.7 | — |
| Hans Schambye | Option | 31,237 | 7.49 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Carl Goldfischer, M.DIndependent · Audit · Departed during FY | $121,332 | — | $3,590 | — | — | $124,922 |
| Jayson Dallas, M.DIndependent · Audit · Departed during FY | 60,000 | — | 1,795 | — | — | 61,795 |
| Amit D. MunshiIndependent · Audit · Departed during FY | 58,533 | — | 1,795 | — | — | 60,328 |
| David Shapiro, M.DIndependent · Departed during FY | 46,929 | — | 3,595 | — | — | 50,524 |
| Amy WechslerIndependent | 42,663 | — | 3,595 | — | — | 46,258 |
| Anne Prener, M.DIndependent · Departed during FY | 40,530 | — | 3,595 | — | — | 44,125 |
| Julianne BrunoIndependent · Audit · Compensation · Newly elected | 8,594 | — | 0 | — | — | 8,594 |
| Christopher Cain, Ph.DIndependent · Nominating and Corporate Governance · Compensation (Chair) · Newly elected | 7,099 | — | 0 | — | — | 7,099 |
| Peter HarwinIndependent · Nominating and Corporate Governance (Chair) · Newly elected | 6,726 | — | 0 | — | — | 6,726 |
| Jennifer JarrettEmployee director | — | — | — | — | — | 0 |
| Cameron Turtle, D.PhilIndependent · Audit · Newly elected | — | — | — | — | — | — |
| Michael LandsittelIndependent · Nominating and Corporate Governance · Audit (Chair) · Newly elected | — | — | — | — | — | — |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 10,000 / 7,500 / 5,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $392,406 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $392,406 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Damora Therapeutics as a peer
Companies that benchmark against DMRA
No companies currently name DMRA as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Damora Therapeutics, Inc. | 2025 | Hans Schambye | $547,521 | $0 | $73,677 | $0 | $1,299,792 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-17 | 51,401,988 | 3,546 | 27,018 | 99.99% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-17 | 99.99%a |
a. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (19 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Hans Schambye. DEF 14A, filed 2026-04-29. Section “Executive Compensation”. As printed: 1,299,792. View filing ↗
- Section 01, Garrett Winslow. DEF 14A, filed 2026-04-29. Section “Executive Compensation”. As printed: 854,755. View filing ↗
- Section 01, Lori Firmani. DEF 14A, filed 2026-04-29. Section “Executive Compensation”. As printed: 563,211. View filing ↗
- Section 08, Carl Goldfischer, M.D. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 124,922. View filing ↗
- Section 08, Jayson Dallas, M.D. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 61,795. View filing ↗
- Section 08, Amit D. Munshi. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 60,328. View filing ↗
- Section 08, David Shapiro, M.D. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 50,524. View filing ↗
- Section 08, Amy Wechsler. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 46,258. View filing ↗
- Section 08, Anne Prener, M.D. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 44,125. View filing ↗
- Section 08, Julianne Bruno. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 8,594. View filing ↗
- Section 08, Christopher Cain, Ph.D. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 7,099. View filing ↗
- Section 08, Peter Harwin. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 6,726. View filing ↗
- Section 08, Jennifer Jarrett. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Cameron Turtle, D.Phil. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: —. View filing ↗
- Section 08, Michael Landsittel. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: —. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-17. Item 5.07 · say-on-pay result. As reported: 99.99% (votes for as printed: 51,401,988). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 392,406 + equity 0 + all other 0 = 392,406, summed across the director compensation table rows.
- Damora Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Damora Therapeutics, Inc.'s own proxy. As printed: 1,299,792. View filing ↗